Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Context Therapeutics Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Form 8-K reports include Regulation FD corporate presentations, operating and financial results, clinical-trial updates, and the FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.
Proxy and governance filings describe annual meeting matters, director elections, stockholder voting procedures and common stock matters. Charter-related material-event reports document corrections to certificate provisions governing director terms and removal rights, along with associated Delaware court and stockholder-governance disclosures.
Context Therapeutics Inc. filed an agreement to resolve a Delaware stockholder class action by asking the court to invalidate two charter provisions that gave directors three-year terms and allowed removal only for cause. If the court approves the stipulated judgment, these governance provisions will be removed through a Certificate of Correction.
The case would then be dismissed with prejudice, and the company plans to hold its 2026 annual meeting of stockholders on June 24, 2026, with a record date of April 27, 2026. Stockholders must submit proposals or director nominations by 5:00 p.m. EDT on March 14, 2026, and any stockholders using universal proxy rules to solicit for alternate director nominees must give notice by April 13, 2026.
Levit Alex C. reported acquisition or exercise transactions in this Form 4 filing.
Context Therapeutics Inc. reported that Chief Legal Officer and Corporate Secretary Alex C. Levit received a grant of stock options covering 270,000 shares on February 19, 2026. According to the terms, 25% of the options vest on February 19, 2027, with the remainder vesting in equal monthly installments over the following three years, conditioned on continued service.
Minai-Azary Jennifer Lynn reported acquisition or exercise transactions in this Form 4 filing.
Context Therapeutics Inc. reported an insider equity award to its Chief Financial Officer, Jennifer Lynn Minai-Azary. She received a stock option covering 275,000 shares of common stock as a grant, not an open-market purchase or sale.
According to the terms, the option vests over four years. 25% of the option vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, subject to her continued service with the company.
Context Therapeutics Inc. reported that Chief Medical Officer Karen Deborah Chagin acquired a grant of stock options covering 290,000 shares of the company’s stock. The options carry a reported exercise price of $0.0000 per share and are held as direct derivative securities.
According to the vesting terms, 25% of the option award vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, contingent on her continued service with the company.
Context Therapeutics Inc. reported that Chief Executive Officer Martin A. Lehr received a grant of stock options for 815,000 shares at an exercise price of $0.00 per share. The option vests over four years, with 25% vesting on February 19, 2027 and the rest in equal monthly installments over the following three years, contingent on continued service.
Context Therapeutics Inc. received an updated beneficial ownership report showing that investment firm Great Point Partners, LLC, together with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reports beneficial ownership of 4,683,711 shares of common stock, representing 5.10% of the company’s outstanding shares.
The stake is held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., for which Great Point acts as investment manager. The reporting persons state the securities were not acquired to change or influence control of Context Therapeutics and jointly file this Schedule 13G/A.
BioImpact LLC filed an amended Schedule 13G reporting beneficial ownership of 10,679,391 shares of Context Therapeutics Inc. common stock. This represents 11.6% of the outstanding common shares. BioImpact has sole voting and sole dispositive power over all reported shares, with no shared power.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Context Therapeutics, other than activities solely in connection with a nomination under Rule 240.14a-11.
Soleus Capital-affiliated funds have disclosed a 5.2% passive stake in Context Therapeutics Inc. common stock. The group reports beneficial ownership of 4,776,398 shares of Context’s common stock, based on 91,879,177 shares outstanding as of November 4, 2025.
The shares are held directly by Soleus Capital Master Fund, L.P., with related Soleus entities and Guy Levy reporting shared voting and dispositive power and formally disclaiming beneficial ownership beyond Section 13(d) reporting obligations. They certify the holdings were not acquired to change or influence control of Context Therapeutics.
Context Therapeutics Inc. furnished an updated corporate presentation dated January 2026 for use in meetings with investors, analysts and other stakeholders. The presentation is provided as Exhibit 99.1 to this report and is incorporated by reference for informational purposes. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished, not filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings.
Context Therapeutics (CNTX) announced pipeline updates alongside its third-quarter 2025 communication. The company highlighted progress in three bispecific T cell engager programs across early development.
CTIM-76 (CLDN6 x CD3) Phase 1: 12 patients enrolled as of October 30, 2025; currently in Cohort 5 with a 140 mcg priming dose and 560 mcg full dose. Preliminary signs of anti-tumor activity, including an ongoing RECIST response, were observed beginning at Cohort 3. No CRS greater than Grade 1, no dose-limiting toxicities, and the maximum tolerated dose has not been reached. The company plans updated interim Phase 1a data and Phase 1b dose selection in the second quarter of 2026.
CT-95 (MSLN x CD3) Phase 1: 6 patients enrolled; in Cohort 3 with a 0.18 µg/kg priming dose and 0.6 µg/kg full dose. Based on preclinical work, target dose exposure is projected starting at Cohort 4. No CRS greater than Grade 2, no DLTs, and no MTD reached. Initial Phase 1a data are anticipated mid‑2026.
CT-202 (Nectin‑4 x CD3): preclinical program expects regulatory filings to support a first‑in‑human trial in the second quarter of 2026.